# Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

> **NCT06145633** · PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 15 (estimated)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **OTHER:** Fludeoxyglucose F-18
- **OTHER:** Gallium Ga 68 Gozetotide
- **DRUG:** Lutetium Lu 177 Vipivotide Tetraxetan
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Single Photon Emission Computed Tomography
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT06145633
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-18
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06145633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06145633, "Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06145633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*